Consistent use combined with balanced eating habits can lead to more meaningful progress
In the context of T2D, we note with particular interest MAESTRO-NASHs criteria for GLP-1s and statins: Glucagon-like peptide 1 [GLP-1] agonist therapy (e.g., albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide) unless stabilised for 24 weeks prior to biopsy
It activates the AMPK pathway, a metabolic superstar that boosts the metabolism of fatty acids and glucose, leading to increased energy expenditure and fat reduction
While overall prescribing of semaglutide increased throughout second quarter of 2024, the rate of first-time prescribing of semaglutide slowed from 0.9% of prescriptions in May 2024 to 0.7% in June 2024
Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, et al
In 2017, the Food and Drug Administration approved a new iteration, Ozempic (semaglutide), as a T2D treatment